Inactivation of AR/TMPRSS2-ERG/Wnt Signaling Networks Attenuates the Aggressive Behavior of Prostate Cancer Cells

The development of prostate cancer and its progression to castrate-resistant prostate cancer (CRPC) after antiandrogen ablation therapy are driven by persistent biological activity of androgen receptor (AR) signaling. Moreover, studies have shown that more than 50% of human prostate cancers overexpress ERG (v-ets avian erythroblastosis virus E26 oncogene related gene) due to AR-regulated TMPRSS2-ERG fusion gene. However, the reported roles of TMPRSS2-ERG fusion in cancer progression are not clear. In this study, we investigated the signal transduction in the AR/TMPRSS2-ERG/Wnt signaling network for studying the aggressive behavior of prostate cancer cells and further assessed the effects of BR-DIM and CDF [natural agents-derived synthetic formulation and analogue of 3,3′-diindolylmethane (DIM) and curcumin, respectively, with improved bioavailability] on the regulation of AR/TMPRSS2-ERG/Wnt signaling. We found that activation of AR resulted in the induction of ERG expression through TMPRSS2-ERG fusion. Moreover, we found that ERG overexpression and nuclear translocation activated the activity of Wnt signaling. Furthermore, forced overexpression of ERG promoted invasive capacity of prostate cancer cells. More important, we found that BR-DIM and CDF inhibited the signal transduction in the AR/TMPRSS2-ERG/Wnt signaling network, leading to the inactivation of Wnt signaling consistent with inhibition of prostate cancer cell invasion. In addition, BR-DIM and CDF inhibited proliferation of prostate cancer cells and induced apoptotic cell death. On the basis of our findings, we conclude that because BR-DIM and CDF downregulate multiple signaling pathways including AR/TMPRSS2-ERG/Wnt signaling, these agents could be useful for designing novel strategies for the prevention and/or treatment of prostate cancer. Cancer Prev Res; 4(9); 1495–506. ©2011 AACR.

[1]  D. Berney,et al.  Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells. , 2010, Cancer research.

[2]  S. Srivastava,et al.  Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence , 2010, Prostate Cancer and Prostatic Diseases.

[3]  R. Matusik,et al.  Wnt/β-Catenin activation promotes prostate tumor progression in a mouse model , 2010, Oncogene.

[4]  Hongtae Kim,et al.  c-Myc stimulates cell invasion by inhibiting FBX8 function , 2010, Molecules and cells.

[5]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[6]  O. Kallioniemi,et al.  FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. , 2010, Cancer research.

[7]  Martin J. Aryee,et al.  Androgen-induced TOP2B mediated double strand breaks and prostate cancer gene rearrangements , 2010, Nature Genetics.

[8]  M. Gleave,et al.  Relaxin drives Wnt signaling through upregulation of PCDHY in prostate cancer , 2010, The Prostate.

[9]  Zhaohui S. Qin,et al.  An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. , 2010, Cancer cell.

[10]  Ayako Nishimoto,et al.  Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity , 2010, The Prostate.

[11]  M. Rubin,et al.  ERG rearrangement metastasis patterns in locally advanced prostate cancer. , 2010, Urology.

[12]  S. Pang,et al.  Ezrin mediates c-Myc actions in prostate cancer cell invasion , 2010, Oncogene.

[13]  M. Walker,et al.  Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells , 2010, Molecular Cancer.

[14]  C. Cordon-Cardo,et al.  Androgen receptor expression is associated with prostate cancer‐specific survival in castrate patients with metastatic disease , 2010, BJU international.

[15]  Jie Zhang,et al.  Nuclear Receptor-Induced Chromosomal Proximity and DNA Breaks Underlie Specific Translocations in Cancer , 2009, Cell.

[16]  S. Varambally,et al.  Induced Chromosomal Proximity and Gene Fusions in Prostate Cancer , 2009, Science.

[17]  K. Waltering,et al.  Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. , 2009, Cancer research.

[18]  Shadan Ali,et al.  Fluorocurcumins as Cyclooxygenase-2 Inhibitor: Molecular Docking, Pharmacokinetics and Tissue Distribution in Mice , 2009, Pharmaceutical Research.

[19]  S. Balk,et al.  Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer. , 2009, Cancer research.

[20]  F. Saad,et al.  PTEN genomic deletion is associated with p‐Akt and AR signalling in poorer outcome, hormone refractory prostate cancer , 2009, The Journal of pathology.

[21]  C. Sander,et al.  Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis , 2009, Nature Genetics.

[22]  Pier Paolo Pandolfi,et al.  Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate , 2009, Nature Genetics.

[23]  G. Jenster,et al.  Overexpression of Prostate-Specific TMPRSS2(exon 0)-ERG Fusion Transcripts Corresponds with Favorable Prognosis of Prostate Cancer , 2009, Clinical Cancer Research.

[24]  Dong-Eun Kim,et al.  Natural derivatives of curcumin attenuate the Wnt/beta-catenin pathway through down-regulation of the transcriptional coactivator p300. , 2008, Biochemical and biophysical research communications.

[25]  C. Abbou,et al.  Comparative expression of Hedgehog ligands at different stages of prostate carcinoma progression , 2008, The Journal of pathology.

[26]  S. Hayward,et al.  Prostate tumor progression is mediated by a paracrine TGF-β/Wnt3a signaling axis , 2008, Oncogene.

[27]  K. Tsui,et al.  Curcumin blocks the activation of androgen and interlukin-6 on prostate-specific antigen expression in human prostatic carcinoma cells. , 2008, Journal of andrology.

[28]  M. Ittmann,et al.  Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. , 2008, Cancer research.

[29]  W. Birchmeier,et al.  Wnt signalling and its impact on development and cancer , 2008, Nature Reviews Cancer.

[30]  P. Nelson,et al.  A causal role for ERG in neoplastic transformation of prostate epithelium , 2008, Proceedings of the National Academy of Sciences.

[31]  Robert A Newman,et al.  Bioavailability of curcumin: problems and promises. , 2007, Molecular pharmaceutics.

[32]  J. Trachtenberg,et al.  Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer , 2007, British Journal of Cancer.

[33]  Zhiwei Wang,et al.  Regulation of FOXO3a/β-Catenin/GSK-3β Signaling by 3,3′-Diindolylmethane Contributes to Inhibition of Cell Proliferation and Induction of Apoptosis in Prostate Cancer Cells* , 2007, Journal of Biological Chemistry.

[34]  S. Leung,et al.  Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers , 2007, Journal of Clinical Pathology.

[35]  L. Klotz,et al.  Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression , 2007, Cancer biology & therapy.

[36]  M. Rubin,et al.  TMPRSS2-ERG Fusion Prostate Cancer: An Early Molecular Event Associated With Invasion , 2006, The American journal of surgical pathology.

[37]  O. Kallioniemi,et al.  TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. , 2006, Cancer research.

[38]  Zhiwei Wang,et al.  Down-regulation of androgen receptor by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells. , 2006, Cancer research.

[39]  S. Terry,et al.  Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer , 2006, Journal of cellular biochemistry.

[40]  S. Terry,et al.  Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells , 2006, Oncogene.

[41]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[42]  Shadan Ali,et al.  Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. , 2005, Cancer research.

[43]  Donald J L Jones,et al.  Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. , 2005, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[44]  A. Potti,et al.  Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. , 2004, Cancer.

[45]  Donald E Mager,et al.  Physiological modeling of formulated and crystalline 3,3'-diindolylmethane pharmacokinetics following oral administration in mice. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[46]  M. Buendia,et al.  Acetylation of β-Catenin by p300 Regulates β-Catenin-Tcf4 Interaction , 2004, Molecular and Cellular Biology.

[47]  M. Rubin,et al.  β-Catenin-related Anomalies in Apoptosis-resistant and Hormone-refractory Prostate Cancer Cells , 2003 .

[48]  Randall T. Moon,et al.  The transcriptional coactivator CBP interacts with beta-catenin to activate gene expression. , 2000, The Journal of cell biology.

[49]  B. Bao,et al.  Inactivation of AR / TMPRSS 2-ERG / Wnt Signaling Networks Attenuates the Aggressive Behavior of Prostate Cancer Cells , 2011 .

[50]  Zhiwei Wang,et al.  Regulation of FOXO3a/beta-catenin/GSK-3beta signaling by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells. , 2007, The Journal of biological chemistry.

[51]  M. Rubin,et al.  Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[52]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.